Processing with anti-tumor necrosis factor-α (TNF-α) antibody has resulted in an improved remission maintenance rate; however, the dosage effect, increased susceptibility to infections, and development of neutralizing antibodies still present a challenge. This evidence concerns the gene TNF and infection.